What Is a GLP-1 Agonist?

GLP-1 agonists are some of the most talked-about medications of the decade. You may know them by brand names like Ozempic, Wegovy or Zepbound. This guide explains what the term means, how these drugs work in the body, and which ones the FDA has approved so far.

Key takeaways

• GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat.
• A GLP-1 agonist is a medication that switches on the same receptor as that hormone, but lasts much longer.
• These drugs help control blood sugar, slow stomach emptying and reduce appetite.
• Some are FDA-approved for type 2 diabetes, some for weight management, and some for both, plus other conditions like heart risk and sleep apnea.
• They are prescription medications. A licensed prescriber decides which one, the dose and the schedule.

What GLP-1 is in the first place

Your body makes GLP-1 in the intestine when food arrives. It is a small peptide hormone, a short chain of amino acids. Once released, it sends a few useful signals:

• It tells the pancreas to release insulin when blood sugar is rising.
• It tells the pancreas to release less glucagon, a hormone that raises blood sugar.
• It slows how fast the stomach empties, so you feel full longer.
• It acts on appetite centers in the brain, which can lower hunger.

The catch is that natural GLP-1 breaks down within a few minutes. That is far too short to use as a treatment.

What "agonist" means

An agonist is anything that binds to a receptor and turns it on. A GLP-1 receptor agonist is a lab-made molecule that fits the GLP-1 receptor and activates it, much like the natural hormone. The big difference is how long it lasts. Drug makers changed the structure so the body breaks it down slowly. Depending on the medication, one dose can last a day or a full week.

You will see a few names used for the same idea: GLP-1 agonist, GLP-1 receptor agonist, GLP-1 RA, or simply "GLP-1s."

How these medications affect the body

Because they act in several places at once, GLP-1 agonists have more than one effect.

Blood sugar

They help the pancreas respond to food with the right amount of insulin. This is glucose-dependent, so on their own they carry a low risk of very low blood sugar. That risk goes up when they are combined with insulin or sulfonylureas, which is why your prescriber may adjust other medicines.

Appetite and fullness

Slower stomach emptying plus signals to the brain often mean people feel full sooner and think about food less. This is the main reason they lead to weight loss.

Heart, kidney and other effects

Large trials have looked at outcomes beyond weight and blood sugar. Some products now carry FDA-approved indications for lowering the risk of major heart events, slowing kidney disease in people with type 2 diabetes, treating a type of fatty liver disease (MASH), or treating obstructive sleep apnea. Each indication belongs to a specific product, not to the whole class.

FDA-approved GLP-1 medications (as of October 2026)

This table covers the main products people ask about. Labels change, so always check the current prescribing information.

A few notes on this list. Tirzepatide is a dual agonist that also acts on the GIP receptor. Orforglipron is a small-molecule pill, not a peptide, approved in April 2026. Generic liraglutide versions of Victoza and Saxenda are now available. AstraZeneca discontinued the exenatide brands Byetta and Bydureon BCise in late 2024. You can read more on our semaglutide page.

What GLP-1 agonists are not

Because they are popular, a lot of confusion surrounds them.

• They are not a cure. Obesity and type 2 diabetes are long-term conditions. Studies show that when people stop these drugs, weight and blood sugar often drift back. See what happens when you stop a GLP-1.
• They are not interchangeable. Each product has its own label, dose steps and approved uses. The FDA label says not to combine semaglutide with other GLP-1 agonists.
• They are not for everyone. Labels include a boxed warning about thyroid C-cell tumors seen in rodents, and the drugs are not recommended for people with a personal or family history of medullary thyroid cancer or MEN 2. Other warnings cover pancreatitis, gallbladder problems, kidney injury from dehydration and more.
• "Research use only" products are not the same thing. Products sold online as "not for human consumption" are not FDA-approved medications, and the FDA has warned consumers not to buy them.

Common side effects in brief

Stomach and gut effects are the most common: nausea, diarrhea, vomiting, constipation and belly discomfort. They tend to show up when starting or after a dose increase. That is why doses start low and rise slowly. Our post on common GLP-1 side effects goes deeper.

How to talk to your provider

If you think a GLP-1 medication might fit you, bring a list of your current medicines, your health history (including thyroid, pancreas and gallbladder history) and your goals. Ask which product fits your situation, what the dose steps look like, and how you will check progress. If you start one, a simple log of doses and symptoms can make follow-up visits easier. The PepSteady app is built for that.

The bottom line

A GLP-1 agonist is a long-acting copy of a natural gut hormone that helps with blood sugar, fullness and appetite. Several are FDA-approved for different conditions, and each one has its own label. Work with a licensed prescriber to decide if one fits you.

Sources

• Wegovy prescribing information (FDA, revised 2026)
• Zepbound prescribing information (FDA, revised 04/2026)
• FDA approves orforglipron, an oral GLP-1 for adults with obesity (Healio)
• FDA's concerns with unapproved GLP-1 drugs used for weight loss
• Discontinuation of Bydureon BCise and Byetta (UnitedHealthcare)

Frequently asked questions